Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Regulatory News In Brief

This article was originally published in The Gray Sheet

Executive Summary

Bird flu, special controls: Influenza A subtype tests and reagents are officially Class II medical devices following the March 22 release of a final rule and special controls 1guidance document detailing the 510(k) requirements for such products. The Centers for Disease Control & Prevention won clearance for the first rapid H5 subtype test to help identify avian flu cases through an expedited de novo 510(k) application in February (2"The Gray Sheet" Feb. 6, 2006, p. 11). Several firms are developing avian flu tests, including Toronto-based Tm Bioscience...
Advertisement

Related Content

FDA’s Accelerated Review Of Flu Test Offers A Model For Future Products
FDA’s Accelerated Review Of Flu Test Offers A Model For Future Products
Concept Papers Seek Industry Input On Combo Product Issues
Device Use In Home Health Setting Surveyed As Part Of CDRH Strategic Plan
Advertisement
UsernamePublicRestriction

Register

MT023400

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel